metabolic funding
34 open opportunities tagged metabolic, across federal agencies and private foundations. Sorted by deadline.
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileNIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileFiscal Year 2027 Expanding Nutrition Services
The purpose of Fiscal Year (FY) 2027 Expanding Nutrition Services (ENS) funding is to increase access to nutrition services at HRSA-funded health centers. Nutrition services can help to prevent, manage, and treat diseases and conditions through nutritional and food-based interventions.
Review criteria on fileLimited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Research Objectives The NIEHS invites qualified investigators from domestic institutions of higher education to submit an application for an SRP Center grant.
22 review criteria on fileSingle Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)
This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from an eligible organization to apply. Please see Section III.
7 review criteria on fileSingle Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)
This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite application(s) from eligible organization(s) to apply. Please see Section III.
7 review criteria on filePriority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that aligns with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR).
3 review criteria on fileMechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics.
3 review criteria on fileNIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
Purpose This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected previously.
4 review criteria on fileCausal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)
6 years.25 billion fewer life years for the United States population.
3 review criteria on fileStimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood…
3 review criteria on fileMechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather…
3 review criteria on fileAdvancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
This notice of funding opportunity (NOFO) invites applications designed to examine the efficacy and clinical effectiveness of multimodality digital health technology approaches to the remote management of diabetes.
3 review criteria on fileContinuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
Cardiovascular complications remain the leading cause of death among individuals with T1D despite the management of traditional risk factors such as high blood glucose, high blood pressure, and elevated cholesterol.
3 review criteria on fileOptimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
Purpose This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use.), and quality of life and be feasible to implement in clinical care settings.
3 review criteria on fileOptimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
Purpose This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a new consortium with clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use.
7 review criteria on fileINCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
The INCLUDE Transformative Research Award Program supports collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in understanding the biology of Down syndrome or related co-occurring conditions, or development of new treatments for…
3 review criteria on fileMaximizing the Scientific Value of Data Generated by the Environmental influences on Child Health Outcomes (ECHO) Program: Dissertation Grant (R36 - Clinical Trial Not Allowed)
The goal of this funding opportunity is to support doctoral candidates studying high-priority areas of child health for the completion of their doctoral dissertation research project.
3 review criteria on fileINCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of new exploratory and developmental research projects that address important gaps in Down syndrome research.
3 review criteria on fileINCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
Purpose The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome.
3 review criteria on fileLimited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a limited-competition program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support during the latter years of the award period of their K award.
3 review criteria on fileMechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact…
3 review criteria on fileMechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather…
3 review criteria on filePRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Purpose Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) NOFOs seek to spur on the development of innovative, reliable, cost-effective, and sustainable multimodal AI-based clinical decision support (CDS) tools with the potential for transformational impact.
3 review criteria on fileNCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
, botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence.
3 review criteria on fileNCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
, botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence.
3 review criteria on fileNutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) invites applications for Nutrition Obesity Research Center (NORC) grants to support research in nutrition and/or obesity.
13 review criteria on fileNCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
, botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence.
3 review criteria on fileMaximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
The goal of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support promising candidates during their mentored postdoctoral training under the guidance of appropriate faculty sponsors.
6 review criteria on fileAgriculture and Food Research Initiative Competitive Grants Program Foundational and Applied Science Program
The AFRI Foundational and Applied Science Program supports grants in six AFRI priority areas to advance knowledge in both fundamental and applied sciences important to agriculture.
Review criteria on fileDiabetes Research Centers (P30 Clinical Trial Optional)
Background According to the CDC, the prevalence of diabetes mellitus in the United States continues to rise over time.6% of the US Population) and about twice that prevalence in those over 65.
9 review criteria on fileNanoscale Interactions
The Nanoscale Interactions program is part of theEnvironmental Engineering and Sustainabilitycluster, which also includes: 1) the Environmental Engineering program; and 2) the Environmental Sustainability program.
2 review criteria on file · agency frameworkPlant Biotic Interactions
The Plant Biotic Interactions (PBI) program supports research on the processes that mediate beneficial and antagonistic interactions between plants and their viral, bacterial, oomycete, fungal, plant, and invertebrate symbionts, pathogens and pests.
2 review criteria on file · agency frameworkCellular and Biochemical Engineering
Synopsis TheCellular and Biochemical Engineering(CBE)program is part of theEngineering Biology and Healthcluster, which also includes: 1) theBiophotonicsprogram; 2) theBiosensingprogram; 3) theDisability and Rehabilitation Engineeringprogram; and 4) theEngineering of Biomedical Systemsprogram.
2 review criteria on file · agency frameworkSee which metabolic opportunities fit your work
An account is free and shows the full announcement, the review criteria reviewers score you against, and whether you are actually eligible — including the windows that close before the deadline does.
No card required.